Press Releases
Valiltramiprosate is an investigational agent and not approved for use anywhere in the world. Statements in news stories may be aspirational.
Alzheon to Present Baseline Imaging Characteristics from Ongoing APOLLOE4 Phase 3 Trial of Oral Tablet ALZ-801 (Valiltramiprosate) and Positive Biomarker/Clinical Correlations from Phase 2 Biomarker Study at Alzheimer’s Association International Conference in Amsterdam
Reduction of Hippocampal Atrophy and Lateral Ventricle Enlargement Correlates with Clinical Benefit of ALZ-801 in APOE4 Carriers with Early AD
Alzheon to Present Baseline Imaging Characteristics from Ongoing APOLLOE4 Phase 3 Trial of Oral Tablet ALZ-801 (Valiltramiprosate) and Results of Phase 2 Biomarker Study at American Academy of Neurology Conference in Boston
Alzheimer’s Disease (AD) Patients with APOE4/4 Homozygous Genotype Show More Frequent Cerebral Amyloid Angiopathy (CAA) Lesions at Baseline CAA Pathology Increases Risk of Treatment-Induced Brain Edema [...]
Alzheon to Present Biomarker, Brain Preservation and Clinical Effects of Oral Tablet ALZ-801 (Valiltramiprosate) at Upcoming AD/PD 2023 Conference in Gothenburg, Sweden
Industry-Leading Results Position ALZ-801 to Potentially Become the First Oral Agent that Can Slow or Even Stop and Prevent Alzheimer’s Pathology in Patients and Healthy Individuals at Risk for the Disease
Alzheon Announces Early Completion of Enrollment of APOLLOE4 Phase 3 Clinical Trial Evaluating Oral ALZ-801 (Valiltramiprosate) in APOE4/4 Homozygotes with Early Alzheimer’s Disease
Pivotal Phase 3 Trial Completed Enrollment Ahead of Schedule Enabling Topline Data Readout and NDA Filing in 2024
Alzheon to Present Industry-Leading Biomarker, Brain Preservation, and Clinical Effects with Oral ALZ-801 (Valiltramiprosate) at 15th Annual Clinical Trials in Alzheimer’s Disease Conference
New Results Position ALZ-801 to Potentially Become the First Oral Agent that Can Slow or Even Stop and Prevent Alzheimer’s Pathology in Patients and Healthy Individuals at Risk for the Disease
Alzheon Reports Industry-Leading Biomarker, Brain Preservation and Clinical Effects Following 12 Months of Treatment in Phase 2 Trial of Oral ALZ-801 (Valiltramiprosate) in Patients with Early Alzheimer’s Disease
41% Reduction in Plasma P-tau181 from Baseline to 12 Months, Suggests Robust Disease Modification in Carriers of One or Two Copies of APOE4 Gene who Represent Two Thirds of Alzheimer’s Patients
Alzheon Appoints Glenn Pauly as Head of Commercial
New Executive Joins Leadership Team to Build Commercial Infrastructure for Launch of Oral Tablet ALZ-801 (Valiltramiprosate) in Alzheimer’s Disease
Alzheon to Present Industry-Leading Phase 2 Biomarker and Clinical Data with ALZ-801 (Valiltramiprosate) Oral Tablet at 2022 Alzheimer’s Association International Conference
Several-Fold Greater Reduction on P-tau181 Compared to Anti-Amyloid Antibodies Validates Superior Clinical Benefit from Prior Studies in Alzheimer’s Patients
Alzheon to Present ALZ-801 (Valiltramiprosate) Oral Tablet Program Update as Potential Treatment for Alzheimer’s Disease in Adults with Down Syndrome at 4th International Trisomy 21 Research Conference
New Results Position ALZ-801 to Potentially Become the First Oral Agent that Can Slow or Even Stop and Prevent Alzheimer’s Pathology in Patients and Healthy Individuals at Risk for the Disease
Alzheon Announces Closing of Oversubscribed $50 Million Series D Financing Round to Accelerate Completion of APOLLOE4 Phase 3 Trial and Expansion of Product Portfolio
Proceeds Will Accelerate Both Completion of APOLLOE4 Phase 3 Study Evaluating Oral Tablet ALZ-801 (Valiltramiprosate) and Regulatory Filings for Patients with Early Alzheimer’s Disease
Newsletter
Sign up for updates
Get the latest Alzheon news in your inbox.
Not seeing the signup form? An ad or privacy blocker may be hiding it – email info@alzheon.com and we’ll add you to the list.
